TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular D...(cs business operating in Boston and Pasa...),Health

Date:5/18/2009

cs business operating in Boston and Pasadena in the US to serve the molecular diagnostic market targeting hospitals and reference laboratories. Osmetech has a strong patent portfolio and markets FDA 510(k) cleared first- and second-generation electrochemistry-based array systems, the eSensor(R) 4800 platform and the eSensor(R) XT-8 platform, presently available for Cystic Fibrosis Carrier Detection and Warfarin Sensitivity testing, respectively. The eSensor(R) XT-8 system is designed to support a broad test menu. A cytochrome P450 2C9 genotyping test (RUO) is now available while planned menu expansion includes an extended warfarin panel with the proprietary 4F2 marker, a venous thrombosis panel (Factor II, Factor V Leiden and MTHFR) and a RESPLEX(R) respiratory pathogen assay marketed in collaboration with Qiagen that is capable of detecting Swine Flu. For more information about the company and products, call (800) eSensor (373-6767), email OMDInformation@osmetech.com, or visit our web site at http://www.osmetech.com.

    Contact:
    Judy Le
    858-546-0004

'/>"/>

SOURCE TriLink BioTechnologies, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. TriLink Launches CleanAmp(TM) dNTPs for Hot Start PCR
2. TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project
3. Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ)
4. DSM Announces Yield Boosts of 5-10 Fold With XD(R) Technology for Mammalian Manufacturing Platforms
5. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
6. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
7. Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
8. AlphaVax Announces Promising Results in Melanoma Studies
9. Tris Pharma Announces Acceptance of Its First Two NDAs
10. Bionovo Announces First Quarter 2009 Highlights and Financial Results
11. ADVENTRX Announces Results From ANX-514 Bioequivalence Study